Letter to the Editor
Page 1 of 2
Low levels of interleukin-10 in patients with transfusion-related acute lung injury Rick Kapur1, Michael Kim2,3, Johan Rebetz1, Matthew T. Rondina4,5,6, Leendert Porcelijn7, John W. Semple1,2,3,8 1
Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden; 2Keenan Research Centre for Biomedical Science, 3The
Toronto Platelet Immunobiology Group, St. Michael’s Hospital, Toronto, ON, Canada; 4Molecular Medicine Program, 5Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA; 6Department of Internal Medicine, George E. Wahlen Salt Lake City VAMC, University of Utah, Salt Lake City, UT, USA; 7Department of Thrombocyte and Leukocyte Serology, Sanquin Diagnostic Services, Amsterdam, The Netherlands; 8
Department of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Correspondence to: Prof. John W. Semple. Division of Hematology and Transfusion Medicine, Lund University, BMC C14, Klinikgatan 26, 221 84 Lund, Sweden. Email: [email protected]. Submitted Mar 31, 2017. Accepted for publication Apr 07, 2017. doi: 10.21037/atm.2017.04.37 View this article at: http://dx.doi.org/10.21037/atm.2017.04.37
Transfusion related acute lung injury (TRALI) is the leading cause of transfusion-related fatalities (FDA Report 2016) (1) and is characterized by the acute onset of respiratory distress within 6 hours following blood transfusion (2,3). The clinical diagnosis is confirmed in case of newly developing acute respiratory distress: PaO2/FiO2 ratio (ratio of arterial oxygen partial pressure to fractional inspired oxygen)
Page 1 of 2
Low levels of interleukin-10 in patients with transfusion-related acute lung injury Rick Kapur1, Michael Kim2,3, Johan Rebetz1, Matthew T. Rondina4,5,6, Leendert Porcelijn7, John W. Semple1,2,3,8 1
Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden; 2Keenan Research Centre for Biomedical Science, 3The
Toronto Platelet Immunobiology Group, St. Michael’s Hospital, Toronto, ON, Canada; 4Molecular Medicine Program, 5Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA; 6Department of Internal Medicine, George E. Wahlen Salt Lake City VAMC, University of Utah, Salt Lake City, UT, USA; 7Department of Thrombocyte and Leukocyte Serology, Sanquin Diagnostic Services, Amsterdam, The Netherlands; 8
Department of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Correspondence to: Prof. John W. Semple. Division of Hematology and Transfusion Medicine, Lund University, BMC C14, Klinikgatan 26, 221 84 Lund, Sweden. Email: [email protected]. Submitted Mar 31, 2017. Accepted for publication Apr 07, 2017. doi: 10.21037/atm.2017.04.37 View this article at: http://dx.doi.org/10.21037/atm.2017.04.37
Transfusion related acute lung injury (TRALI) is the leading cause of transfusion-related fatalities (FDA Report 2016) (1) and is characterized by the acute onset of respiratory distress within 6 hours following blood transfusion (2,3). The clinical diagnosis is confirmed in case of newly developing acute respiratory distress: PaO2/FiO2 ratio (ratio of arterial oxygen partial pressure to fractional inspired oxygen)
